Literature DB >> 14614743

Alterations of liver function test in patients treated with antipsychotics.

M Teresa Garcia-Unzueta1, Andres Herran, Deirdre Sierra-Biddle, J Antonio Amado, J Luis Vázquez-Barquero, Concepción Alvarez.   

Abstract

The prevalence of alterations of liver function tests in patients treated with a wide range of antypsychotics is unknown. The aim of this study was to analyze the effects of antipsychotics on liver function tests in a population of schizophrenic outpatients. Concentrations of AST, ALT, GGT, alkaline phosphatase, albumin, and bilirubin were determined in 54 patients fitting DSM-IV criteria of schizophrenia, and the same number of sex- and age-matched healthy subjects. Assessments included the Clinical Global Impression (CGI) and the Positive and Negative Syndrome Scale (PANSS) in addition to treatment related variables. Transaminases concentrations were slightly elevated in study patients compared to healthy controls, but without statistical significance. Alkaline phosphatase showed higher values in schizophrenic patients. Albumin and bilirubin were lower in study patients. Liver function tests abnormalities were found in about 10% of schizophrenic patients treated with antipsychotics. Treatment with depot phenotiazines induces alteration in these tests more frequently than treatment with other antipsychotics. PANSS negative subscale scores directly correlated with alkaline phosphatase and inversely correlated with albumin. A substantial number of patients in treatment with antipsychotic drugs present alterations of liver function tests. Both pharmacological and clinical factors could be related with these alterations. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614743      PMCID: PMC6807977          DOI: 10.1002/jcla.10094

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  9 in total

Review 1.  Hepatotoxicity of psychotropic drugs.

Authors:  K Selim; N Kaplowitz
Journal:  Hepatology       Date:  1999-05       Impact factor: 17.425

Review 2.  SCAN. Schedules for Clinical Assessment in Neuropsychiatry.

Authors:  J K Wing; T Babor; T Brugha; J Burke; J E Cooper; R Giel; A Jablenski; D Regier; N Sartorius
Journal:  Arch Gen Psychiatry       Date:  1990-06

3.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

4.  [Development and verification of the Spanish version of the "scanning system" psychiatric interview ("Questionnaires for clinical evaluation in neuropsychiatry"].

Authors:  J L Vázquez-Barquero; L Gaite; J Artal Simón; A Arenal; S Herrera Castanedo; J F Díez Manrique; M J Cuesta Núñez; A Higuera
Journal:  Actas Luso Esp Neurol Psiquiatr Cienc Afines       Date:  1994 May-Jun

5.  Fluphenazine decanoate-induced cholestatic jaundice and thrombocytopenia.

Authors:  R J Holt
Journal:  Pharmacotherapy       Date:  1984 Jul-Aug       Impact factor: 4.705

Review 6.  Neuroleptic intolerance.

Authors:  T E Hansen; D E Casey; W F Hoffman
Journal:  Schizophr Bull       Date:  1997       Impact factor: 9.306

7.  Intrahepatic cholestasis and hyperbilirubinemia in ethynyl estradiol and chlorpromazine-treated rats.

Authors:  T Obata
Journal:  Gastroenterol Jpn       Date:  1983-12

8.  Liver disorders in patients receiving chlorpromazine or isoniazid.

Authors:  L E Derby; S P Gutthann; H Jick; A D Dean
Journal:  Pharmacotherapy       Date:  1993 Jul-Aug       Impact factor: 4.705

9.  Effects of neuroleptic phenothiazines on the activities of aminotransferases and gamma-glutamyltransferase in serum and liver.

Authors:  I Cepelak; K Lipovac; D Juretić; Z Birek
Journal:  J Clin Chem Clin Biochem       Date:  1986-08
  9 in total
  5 in total

1.  Response to comments on "Gamma-glutamyl-transferase is associated with incident hip fractures in women and men ≥ 50 years: a large population-based cohort study".

Authors:  Wolfgang Brozek; Hanno Ulmer; Alfonso Pompella; Gabriele Nagel; Andreas Leiherer; Oliver Preyer; Hans Concin; Emanuel Zitt
Journal:  Osteoporos Int       Date:  2022-06-28       Impact factor: 5.071

2.  Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.

Authors:  Julie Kreyenbuhl; Deborah R Medoff; Stephen L Seliger; Lisa B Dixon
Journal:  Schizophr Res       Date:  2008-03-19       Impact factor: 4.939

3.  Association between decreased serum TBIL concentration and immediate memory impairment in schizophrenia patients.

Authors:  Xiao Li Yin; Qiu Fang Jia; Guang Ya Zhang; Jian Ping Zhang; Tomoaki Shirao; Cai Xia Jiang; Xu Yuan Yin; Yan Song Liu; Peng Chen; Xiao Chu Gu; Zheng Kang Qian; Guang Zhong Yin; Hai Sen Xia; Li Hui
Journal:  Sci Rep       Date:  2019-02-07       Impact factor: 4.379

4.  Is Vitamin B12 Level a Reliable Predictor of Psychosis Severity in Male Patients with Megaloblastic Anemia at a Single Tertiary Hospital?

Authors:  Hanaa Wafaa; Rania Magadmi; Nora Hakami; Hadeel Al Sadoun; Safa Almaghrabi; Nuha Mohammed; Aziza Alrafiah
Journal:  Int J Gen Med       Date:  2022-10-04

5.  Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects.

Authors:  Kwang H Choi; Brandon W Higgs; Serge Weis; Jonathan Song; Ida C Llenos; Jeannette R Dulay; Robert H Yolken; Maree J Webster
Journal:  BMC Psychiatry       Date:  2009-09-16       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.